Literature DB >> 28963697

[Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].

A-M Dittrich1.   

Abstract

Pseudomonas aeruginosa (PsA) is a hallmark pathogen of the lung disease in cystic fibrosis (CF) patients. Chronic PsA colonization is a central factor in the course of CF lung disease. PsA contributes considerably to morbidity and mortality, and also has a significant impact on quality of life and the costs of CF treatment. Prevention of chronic colonization has therefore been a major goal in the treatment of CF patients for many years now. In the present article, studies are presented which suggest that prevention of chronic colonization can be achieved. Approaches to prevent chronic PsA colonization are critically evaluated and recommendations for preventative approaches are generated from this discussion.

Entities:  

Keywords:  Chronic colonization; Cystic fibrosis; Microbiology; Prevention; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2017        PMID: 28963697     DOI: 10.1007/s00108-017-0327-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  42 in total

1.  Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Nicole Mayer-Hamblett; Jane L Burns; Sharon McNamara; Frank J Accurso; Michael W Konstan; Barbara A Chatfield; George Retsch-Bogart; David A Waltz; James Acton; Pamela Zeitlin; Peter Hiatt; Richard Moss; Judy Williams; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2007-07

2.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

3.  The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.

Authors:  Reshma Amin; Michelle Lam; Annie Dupuis; Felix Ratjen
Journal:  Pediatr Pulmonol       Date:  2011-02-18

4.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

5.  Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Authors:  Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey
Journal:  Arch Pediatr Adolesc Med       Date:  2011-09

6.  Risk factors for mortality before age 18 years in cystic fibrosis.

Authors:  Susanna A McColley; Michael S Schechter; Wayne J Morgan; David J Pasta; Marcia L Craib; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2017-04-24

7.  Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis.

Authors:  Wanda J Kozlowska; Andrew Bush; Angela Wade; Paul Aurora; Siobhán B Carr; Rosie A Castle; Ah-Fong Hoo; Sooky Lum; John Price; Sarath Ranganathan; Clare Saunders; Sanja Stanojevic; John Stroobant; Colin Wallis; Janet Stocks
Journal:  Am J Respir Crit Care Med       Date:  2008-04-10       Impact factor: 21.405

8.  The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.

Authors:  Kay A Ramsay; Harpreet Sandhu; James B Geake; Emma Ballard; Peter O'Rourke; Claire E Wainwright; David W Reid; Timothy J Kidd; Scott C Bell
Journal:  J Cyst Fibros       Date:  2016-08-08       Impact factor: 5.482

Review 9.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Simon C Langton Hewer; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-04-25

10.  The cystic fibrosis lower airways microbial metagenome.

Authors:  Patricia Moran Losada; Philippe Chouvarine; Marie Dorda; Silke Hedtfeld; Samira Mielke; Angela Schulz; Lutz Wiehlmann; Burkhard Tümmler
Journal:  ERJ Open Res       Date:  2016-05-09
View more
  2 in total

1.  Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.

Authors:  Elena K Schneider-Futschik; Olivia K A Paulin; Daniel Hoyer; Kade D Roberts; James Ziogas; Mark A Baker; John Karas; Jian Li; Tony Velkov
Journal:  ACS Infect Dis       Date:  2018-04-02       Impact factor: 5.084

Review 2.  Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation.

Authors:  Meraj A Khan; Zubair Sabz Ali; Neil Sweezey; Hartmut Grasemann; Nades Palaniyar
Journal:  Genes (Basel)       Date:  2019-02-26       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.